We serve Chemical Name:cyclohexyldichlorophosphine CAS:2844-89-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:cyclohexyldichlorophosphine
CAS.NO:2844-89-5
Synonyms:MFCD00014295;dicyclohexylphosphonous dichloride;Cyclohexylphosphonous dichloride;Dichlorocyclohexylphosphin;Phosphonous dichloride, P-cyclohexyl-;P-Cyclohexyl-Phosphonous Dichloride;Cyclohexylphosphorus dichloride;cyc-C6H11PCl2;cyclohexylphosphonyl dichloride;Cyclohexylphosphonous dichloride Cyclohexylphosphorus dichloride Dichlorocyclohexylphosphin;cyclohexyldichlorophosphine;Dichlorocyclohexylphosphine;cyclohexylphosphorous dichloride
Molecular Formula:C6H11Cl2P
Molecular Weight:185.031
HS Code:2903890090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:214.1±7.0 °C at 760 mmHg
Density:1.2 g/cm3
Index of Refraction:n20/D 1.528
PSA:13.59000
Exact Mass:183.997543
LogP:4.89
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1760
Packing Group:III
Contact us for information like MFCD00014295 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,cyclohexylphosphorous dichloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,cyclohexylphosphonyl dichloride Use and application,Phosphonous dichloride, P-cyclohexyl- technical grade,usp/ep/jp grade.
Related News: Active pharmaceutical ingredients directly impact disease. cyclohexyldichlorophosphine manufacturer Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday. cyclohexyldichlorophosphine supplier Active pharmaceutical ingredients directly impact disease. cyclohexyldichlorophosphine vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. cyclohexyldichlorophosphine factory For example, an active ingredient to relieve pain is included in a painkiller.
